Literature DB >> 2056188

Constitutive expression of multiple growth factor genes by melanoma cells but not normal melanocytes.

U Rodeck1, K Melber, R Kath, H D Menssen, M Varello, B Atkinson, M Herlyn.   

Abstract

In a panel of metastatic melanoma cell lines we found steady-state mRNA transcripts for multiple growth factors including basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGF)-A, PDGF-B, transforming growth factor (TGF)- beta 1, TGF- alpha, melanoma growth-stimulating activity (MGSA), interleukin (IL)-1 alpha, and IL-1 beta but not insulin-like growth factor (IGF)-1 or IGF-2. Expression of growth factor genes was constitutive because prior to RNA extraction melanoma cells were maintained in a chemically defined culture medium free of exogenous growth factors. Each of four cell lines had an individual pattern of expression of either two, four, five, or seven growth factors; however, all cell lines shared expression of the bFGF gene. Two strains of normal melanocytes expressed TGF- beta 1 but not bFGF, PDGF, TGF- alpha , or MGSA mRNA at detectable levels. We tested growth-modulatory effects of the growth factors most frequently expressed by melanoma cells (bFGF, TGF- alpha, TGF- beta, PDGF). None of these stimulated melanoma cell growth consistently, whereas exogenous, acid-activated TGF- beta inhibited melanoma growth at concentrations greater than 10 ng/ml, suggesting that bioactive TGF- beta may represent a physiologic growth inhibitor. Neither neutralizing antisera to PDGF or TGF- alpha nor a monoclonal antibody to the epidermal growth factor (EGF)-receptor inhibited melanoma cell growth. Our results indicate that multiple growth factors are expressed simultaneously and constitutively by melanoma cells but not normal melanocytes in culture. Expression of bFGF is a common feature underscoring the significance of bFGF as an autocrine factor for melanoma cells as described earlier. Secreted PDGF and TGF- alpha are apparently not involved in or not essential for autocrine growth stimulation of melanoma cells.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2056188     DOI: 10.1111/1523-1747.ep12477822

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  Proteomic analysis of laser microdissected melanoma cells from skin organ cultures.

Authors:  Brian L Hood; Jelena Grahovac; Melanie S Flint; Mai Sun; Nuno Charro; Dorothea Becker; Alan Wells; Thomas P Conrads
Journal:  J Proteome Res       Date:  2010-07-02       Impact factor: 4.466

2.  An episomal vector for stable tetracycline-regulated gene expression.

Authors:  M Jost; C Kari; U Rodeck
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  Cross-talk between Dopachrome Tautomerase and Caveolin-1 Is Melanoma Cell Phenotype-specific and Potentially Involved in Tumor Progression.

Authors:  Ioana L Popa; Adina L Milac; Livia E Sima; Petruta R Alexandru; Florin Pastrama; Cristian V A Munteanu; Gabriela Negroiu
Journal:  J Biol Chem       Date:  2016-04-06       Impact factor: 5.157

4.  Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma.

Authors:  M Y Hsu; D T Shih; F E Meier; P Van Belle; J Y Hsu; D E Elder; C A Buck; M Herlyn
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

5.  Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.

Authors:  P C Brooks; R L Klemke; S Schon; J M Lewis; M A Schwartz; D A Cheresh
Journal:  J Clin Invest       Date:  1997-03-15       Impact factor: 14.808

6.  Uveal melanomas express vascular endothelial growth factor and basic fibroblast growth factor and support endothelial cell growth.

Authors:  S R Boyd; D S W Tan; L de Souza; M H Neale; N E Myatt; R A Alexander; M Robb; J L Hungerford; I A Cree
Journal:  Br J Ophthalmol       Date:  2002-04       Impact factor: 4.638

Review 7.  The skin as an immune organ.

Authors:  J K Salmon; C A Armstrong; J C Ansel
Journal:  West J Med       Date:  1994-02

Review 8.  Targeting mutant NRAS signaling pathways in melanoma.

Authors:  Ha Linh Vu; Andrew E Aplin
Journal:  Pharmacol Res       Date:  2016-03-15       Impact factor: 7.658

Review 9.  Role of CXCL1 in tumorigenesis of melanoma.

Authors:  Punita Dhawan; Ann Richmond
Journal:  J Leukoc Biol       Date:  2002-07       Impact factor: 4.962

10.  Inhibitory effect of locally produced and exogenous interleukin-6 on tumor growth in vivo.

Authors:  G J Dougherty; J D Thacker; R S Lavey; A Belldegrun; W H McBride
Journal:  Cancer Immunol Immunother       Date:  1994-05       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.